BIBF 1120 in Recurrent Glioblastoma Multiforme
VEGF inhibition by BEV may induce a change in tumor invasiveness and treatment failure is often associated with remote metastases. BEV may stop the growth of tumor cells by blocking blood flow to the tumor. Cediranib, a pan-VEGF inhibitor has shown promising results in recurrent GBM.
VEGF-blocking with small molecules may overcome the mechanism of resistance, and response to BIBF-1120 in such circumstances may open a new treatment option in GBM. In additional, recurrent glioblastomas have an extremely poor prognosis, so innovative therapies are needed.
|Study Design:||Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Phase II Study of BIBF 1120 in Recurrent Glioblastoma Multiforme|
- Response rate [ Time Frame: Response evaluation every 8 weeks ] [ Designated as safety issue: No ]MacDonald criteria
- Adverse events [ Time Frame: Assessed every 2 weeks ] [ Designated as safety issue: Yes ]CTCAE version 4.0
|Study Start Date:||January 2011|
|Study Completion Date:||August 2012|
|Primary Completion Date:||August 2012 (Final data collection date for primary outcome measure)|
Please refer to this study by its ClinicalTrials.gov identifier: NCT01251484
|Copenhagen, Denmark, 2100|